首页> 外国专利> Monoclonal Antibody CD47 and Its Use in Novels

Monoclonal Antibody CD47 and Its Use in Novels

机译:单克隆抗体CD47及其在小说中的应用

摘要

It refers to a single monoclonal antibody or its immunocompetent component that binds to the forty-seventh session of the Conference on Human Disease Control, including at least 95% variable heavy chain (VH) sequences that match a specific set of amino acid sequences (see ID No. 1, sect. ID No. 3). Page: 1A variable light chain sequence (VL) is identified in at least 95% range with a series of carbamates selected from another group (see, inter alia, ID No. 2, sect. ID No. 4). This monoclonal antibody prevents CD47 from interacting with Senal (Sirpalfa) A regulatory protein and promotes the transmission of hemophilia through large cells of CD47 cells. It also refers to a pharmacological synthesis, including an isolated monoclonal antibody or its fragments, or a bibiotic monoclonal antibody, and a medically acceptable vehicle; preparation methods and their use in the treatment of cancer.Fibrosis or diseases related to blood sugar suppression or platelet addition.
机译:它是指与人类疾病控制会议第四十七届会议结合的单一单克隆抗体或其免疫活性成分,包括至少95%匹配特定氨基酸序列的可变重链(VH)序列(请参见ID号1,ID号3)。页:1A可变轻链序列(VL)在至少95%的范围内与一系列选自另一组的氨基甲酸酯鉴定(尤其参见ID No. 2,ID No. 4)。该单克隆抗体阻止CD47与Senal(Sirpalfa)调节蛋白相互作用,并促进血友病通过CD47细胞的大细胞传播。它还指药理合成,包括分离的单克隆抗体或其片段或生物双抗体,以及医学上可接受的载体。制备方法及其在癌症治疗中的应用。纤维化或与抑制血糖或添加血小板有关的疾病。

著录项

  • 公开/公告号PE20190975A1

    专利类型

  • 公开/公告日2019-07-09

    原文格式PDF

  • 申请/专利权人 I-MAB;

    申请/专利号PE2019000860

  • 申请日2017-10-20

  • 分类号A61K39/395;A61P35;C07K14/705;C07K16;C07K16/18;C07K16/28;

  • 国家 PE

  • 入库时间 2022-08-21 12:01:24

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号